BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28439700)

  • 1. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
    Abid MB; De Mel S; Abid MA; Yap ES; Gopalakrishnan SK; Chen Y; Yuen YC; Wong HC; Lin A; Poon LM; Koh LP; Chng WJ; Tan LK
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
    Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
    Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
    Kroschinsky F; Hölig K; Ehninger G
    Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
    Tricot G; Barlogie B; Zangari M; van Rhee F; Hoering A; Szymonifka J; Cottler-Fox M
    Haematologica; 2008 Nov; 93(11):1739-42. PubMed ID: 18728024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.
    Kim MG; Han N; Lee EK; Kim T
    Bone Marrow Transplant; 2015 Apr; 50(4):523-30. PubMed ID: 25581410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
    Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.
    Patterson AM; Zhang S; Liu L; Li H; Singh P; Liu Y; Farag SS; Pelus LM
    Stem Cell Rev Rep; 2021 Dec; 17(6):2124-2138. PubMed ID: 34510361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.
    Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Magen H; Shimoni A; Nagler A
    Int J Hematol; 2021 Sep; 114(3):363-372. PubMed ID: 34213732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
    Wang X; Ren J; Liang X; He P
    Hematology; 2021 Dec; 26(1):950-955. PubMed ID: 34904529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CD34
    Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
    Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.